Torsdag 28 Maj | 20:07:03 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-26 08:00 Kvartalsrapport 2026-Q2
2026-05-04 - Årsstämma
2026-03-31 - X-dag ordinarie utdelning FARON 0.00 EUR
2026-03-04 - Bokslutskommuniké 2025
2025-08-27 - Kvartalsrapport 2025-Q2
2025-03-24 - X-dag ordinarie utdelning FARON 0.00 EUR
2025-03-21 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-03-25 - X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22 - Årsstämma
2024-03-14 - Bokslutskommuniké 2023
2023-08-29 - Kvartalsrapport 2023-Q2
2023-03-27 - X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24 - Årsstämma
2023-03-03 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-07-07 - Extra Bolagsstämma 2022
2022-04-25 - X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22 - Årsstämma
2022-03-25 - Bokslutskommuniké 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-26 - X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23 - Årsstämma
2021-03-25 - Bokslutskommuniké 2020
2020-05-14 - X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13 - Årsstämma
2020-03-20 - Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriBioteknik
Faron Pharmaceuticals är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som huvudsaklig kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-05-28 15:00:00

Faron Pharmaceuticals Ltd | Company announcement | May 28, 2026 at 16:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)

1. Identity of the issuer:
Faron Pharmaceuticals Oy
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.

3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation
City and country of residence:
Wilmington, DE, Unites States of America
4. Full name of shareholder(s) (if different from 3.):
-
5. Date on which the threshold was crossed or reached:
26.5.2026
6. Total positions of person(s) subject to the notification obligation:

% of shares and voting rights
(total of 7.A)
% of shares and voting rights through financial instruments
(total of 7.B)
Total of both in % (7.A + 7.B)Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached0.109.369.46203,045,511
Position of previous notification (if applicable)n/an/an/a

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)
Number of shares and voting rights% of shares and voting rights
Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
FI40001533090207,70800.10
-----
-----
SUBTOTAL A207,708
0.10



B: Financial Instruments according to SMA 9:6a
Type of financial instrumentExpiration
date
Exercise/
Conversion Period
Physical or cash settlementNumber of shares and voting rights% of shares and voting rights
Rights of Usen/an/an/a18,798,2769.26








Swaps15/10/2027n/aCash201,2760.10



SUBTOTAL B18,999,552
9.36



8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name% of shares and voting rights% of shares and voting rights through financial instrumentsTotal of both
Bank of America CorporationClick here to enter text.Click here to enter text.Click here to enter text.
NB Holdings CorporationClick here to enter text.Click here to enter text.Click here to enter text.
BofAML Jersey Holdings LimitedClick here to enter text.Click here to enter text.Click here to enter text.
BofAML EMEA Holdings 2 LimitedClick here to enter text.Click here to enter text.Click here to enter text.
ML UK Capital Holdings Limited

Merrill Lynch International

Bank of America Corporation

NB Holdings Corporation

BAC North America Holding Company

Bank of America, National Association

Bank of America Coporation

NB Holdings Corporation

BofA Securities, Inc
Click here to enter text.



















9.26%




















9.26%

9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.


10. Additional information:
-





Done at London, United Kingdom on 27.5.2026.